Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Strategic Alliance Partners

July 30, 2024

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

February 19, 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

February 19, 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

February 12, 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

February 12, 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

February 05, 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

February 05, 2024

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

January 30, 2024

Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.

January 30, 2024

Experts delve into the optimal positioning of BCMA-targeted CAR-T therapies in the treatment plan for Relapsed/Refractory Multiple Myeloma (R/R MM), providing valuable perspectives on strategic considerations in myeloma care.

January 29, 2024

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

January 29, 2024

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

January 23, 2024

Dr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).

January 23, 2024

Experts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.

January 22, 2024

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

January 22, 2024

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

January 16, 2024

Noopur Raje, MD discusses the rationale for utilizing BCMA-targeted CAR-T cell therapy in myeloma patients and uncover the similarities and differences when compared to BCMA bispecific.

January 16, 2024

Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.

January 15, 2024

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

January 15, 2024

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

January 15, 2024

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.